senoj, Biota Management was heavily promoting GSK ?1-stop shop? to shareholders and even told shareholders to expect Relenza to drop off from the media headlines. Every time GSK hit the press it was promoting vaccines and the sales result released for the last quarter reflected Relenza market share losing ground to Tamiflu.
And management has the audacity to tell shareholders GSK does not provide detailed information on Relenza sales. Management stooges on HC propped the stupid excuse stating the Relenza license was signed decades ago thinking shareholders are stupid. The current management team had the opportunities to strengthen the licensing agreement when negotiating to settle for $20m especially after GSK had offered to settle for $100m a year earlier.
What will stop management from selling out shareholders again by offering LANI to GSK for a song?
BTA Price at posting:
$1.11 Sentiment: Sell Disclosure: Not Held
